ABBV AbbVie Inc

$230.84

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

AbbVie's upcoming earnings report on July 31st is poised to capture investor attention, particularly given the company's substantial market cap of over $334 billion, which underscores its significant presence in the pharmaceutical sector. Analysts are anticipating an EPS of $2.94, while the whisper number suggests a slightly more optimistic expectation of $3.04, indicating a positive sentiment among some investors. With a revenue estimate of $14.99 billion, AbbVie continues to demonstrate robust financial health, driven by its strong portfolio of immunology and oncology products. Despite the absence of recent news, the company's strategic focus on expanding its pipeline and optimizing its product mix remains a key driver of its growth trajectory. As investors await the earnings release, the whisper number serves as a benchmark for AbbVie's ability to exceed market expectations and sustain its momentum in a competitive landscape.

Updated On 1/6/2026

About AbbVie Inc

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Website: https://www.abbvie.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1551152
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, US
Valuation
Market Cap
$306.02B
P/E Ratio
72.38
PEG Ratio
0.38
Price to Book
92.03
Performance
EPS
$2.39
Dividend Yield
3.79%
Profit Margin
7.59%
ROE
62.30%
Technicals
50D MA
$199.44
200D MA
$187.99
52W High
$216.66
52W Low
$148.19
Fundamentals
Shares Outstanding
2B
Target Price
$210.93
Beta
0.54

ABBV EPS Estimates vs Actual

Estimated
Actual

ABBV News & Sentiment

Dec 31, 2025 • MarketBeat SOMEWHAT-BULLISH
VIRGINIA RETIREMENT SYSTEMS ET Al Grows Stake in AbbVie Inc. $ABBV
VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in AbbVie Inc. by 48.9% in the third quarter, acquiring 96,200 additional shares to reach a total of 293,111 shares valued at $67.9 million. This move comes as AbbVie reported strong Q3 earnings, beating analyst estimates with $1.86 EPS and $15.78 billion in revenue, prompting an increase in its quarterly dividend to $1.73. Institutional ownership of AbbVie stands at 70.23%, with major firms like Vanguard and Geode Capital Management also increasing their positions, and analysts maintaining a "Moderate Buy" consensus with a $245.84 target price.
Dec 31, 2025 • MarketBeat SOMEWHAT-BULLISH
AbbVie Inc. $ABBV Shares Acquired by Smith Salley Wealth Management
Smith Salley Wealth Management increased its holdings in AbbVie Inc. by 3.2% in the third quarter, now owning 158,917 shares valued at $36.8 million. Other institutional investors have also adjusted their stakes, with hedge funds and institutional investors collectively owning 70.23% of the company's stock. AbbVie recently reported strong earnings, beating consensus estimates, and announced an increased quarterly dividend of $1.73 per share, representing a 3.0% yield.
Dec 31, 2025 • MarketBeat BULLISH
Generate Investment Management Ltd Increases Position in AbbVie Inc. $ABBV
Generate Investment Management Ltd has significantly increased its holdings in AbbVie Inc. (NYSE:ABBV) by 91.8% in the third quarter, bringing its total ownership to 86,669 shares valued at $20.07 million. This move comes as other institutional investors have also adjusted their positions in the pharmaceutical giant. AbbVie recently reported strong quarterly earnings, surpassing analyst estimates, and increased its quarterly dividend payment, signaling positive financial health and a commitment to shareholder returns.
Dec 31, 2025 • MarketBeat SOMEWHAT-BULLISH
Simplify Asset Management Inc. Boosts Stock Holdings in AbbVie Inc. $ABBV
Simplify Asset Management Inc. significantly increased its stake in AbbVie Inc. by 100.6% in the third quarter, now holding 36,883 shares valued at $8.54 million. AbbVie maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $245.84, and recently announced a quarterly dividend increase to $1.73 per share. Despite the dividend increase, the company's dividend payout ratio is noted as unusually high at approximately 497%.
Dec 31, 2025 • MarketBeat BULLISH
AbbVie Inc. $ABBV Shares Purchased by Brendel Financial Advisors LLC
Brendel Financial Advisors LLC significantly increased its stake in AbbVie Inc. ($ABBV) by 248.4% in Q3, making AbbVie its third-largest holding. This comes as AbbVie surpassed Q3 earnings expectations and issued strong Q4 2025 guidance, leading to a consensus "Moderate Buy" rating from analysts. The company also raised its quarterly dividend, though its payout ratio is notably high.
Dec 31, 2025 • MarketBeat BULLISH
Diversified Trust Co Purchases 10,891 Shares of AbbVie Inc. $ABBV
Diversified Trust Co increased its stake in AbbVie Inc. (NYSE:ABBV) by 23.6% in the third quarter, acquiring an additional 10,891 shares and bringing its total holdings to 57,076 shares valued at $13.215 million. Other institutional investors also adjusted their positions in ABBV. The article also details AbbVie's stock performance, recent earnings, dividend increase, and updated analyst ratings.
Sentiment Snapshot

Average Sentiment Score:

0.277
50 articles with scored sentiment

Overall Sentiment:

Bullish

ABBV Reported Earnings

Jul 31, 2025
Jun 30, 2025 (Pre market)
0.06 Surprise
  • Reported EPS: $2.97
  • Estimate: $2.91
  • Whisper:
  • Surprise %: 2.1%
Apr 25, 2025
Mar 31, 2025 (Pre market)
0.06 Surprise
  • Reported EPS: $2.46
  • Estimate: $2.40
  • Whisper:
  • Surprise %: 2.5%
Jan 31, 2025
Dec 31, 2024 (Pre market)
0.04 Surprise
  • Reported EPS: $2.16
  • Estimate: $2.12
  • Whisper:
  • Surprise %: 1.9%
Oct 30, 2024
Sep 30, 2024 (Pre market)
0.08 Surprise
  • Reported EPS: $3.00
  • Estimate: $2.92
  • Whisper:
  • Surprise %: 2.7%
Jul 25, 2024
Jun 30, 2024 (Pre market)
0.08 Surprise
  • Reported EPS: $2.65
  • Estimate: $2.57
  • Whisper:
  • Surprise %: 3.1%
Apr 26, 2024
Mar 31, 2024 (Pre market)
0.08 Surprise
  • Reported EPS: $2.31
  • Estimate: $2.23
  • Whisper:
  • Surprise %: 3.6%
Feb 02, 2024
Dec 31, 2023 (Pre market)
0.02 Surprise
  • Reported EPS: $2.79
  • Estimate: $2.77
  • Whisper:
  • Surprise %: 0.7%
Oct 27, 2023
Sep 30, 2023 (Pre market)
0.09 Surprise
  • Reported EPS: $2.95
  • Estimate: $2.86
  • Whisper:
  • Surprise %: 3.1%
Jul 27, 2023
Jun 30, 2023 (Pre market)
0.1 Surprise
  • Reported EPS: $2.91
  • Estimate: $2.81
  • Whisper:
  • Surprise %: 3.6%

Financials